Evotec Balance Sheet Health
Financial Health criteria checks 4/6
Evotec has a total shareholder equity of €968.5M and total debt of €470.1M, which brings its debt-to-equity ratio to 48.5%. Its total assets and total liabilities are €2.0B and €1.0B respectively.
Key information
48.5%
Debt to equity ratio
€470.05m
Debt
| Interest coverage ratio | n/a |
| Cash | €303.27m |
| Equity | €968.47m |
| Total liabilities | €1.02b |
| Total assets | €1.99b |
Recent financial health updates
Recent updates
Evotec: Weak Performance, But Long-Term Potential Is There
Aug 30Evotec: Still A Speculative Buy After A Significant Decline
Apr 24Amgen joins TIAP, Evotec at innovation hub for forming life science companies
Oct 17Evotec stock dips despite US DoD contract up to $49.9M to develop antibody for plague
Sep 20Evotec to acquire Central Glass Germany to bolster drug substance manufacturing
Aug 25Evotec stock falls amid pact with Alpine for commercial process for potential lupus drug ALPN-303
Aug 10Boehringer, Evotec, bioMérieux form joint venture Aurobac to combat antimicrobial resistance
Jul 06Financial Position Analysis
Short Term Liabilities: EVO's short term assets (€698.1M) exceed its short term liabilities (€333.6M).
Long Term Liabilities: EVO's short term assets (€698.1M) exceed its long term liabilities (€688.7M).
Debt to Equity History and Analysis
Debt Level: EVO's net debt to equity ratio (17.2%) is considered satisfactory.
Reducing Debt: EVO's debt to equity ratio has reduced from 68.8% to 48.5% over the past 5 years.
Debt Coverage: EVO's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if EVO's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 02:07 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Evotec SE is covered by 35 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Volker Bosse | Baader Helvea Equity Research |
| Laura Lopez Pineda | Baader Helvea Equity Research |
| Gerhard Schwarz | Baader Helvea Equity Research |